Authors: Proctor, SJ Taylor, PRA Angus, B Wood, K Lennard, AL Lucraft, H Carey, PJ Stark, A Iqbal, A Haynes, A Russel, N Leonard, RCF Culligan, D Conn, J Jackson, GH

Citation: Sj. Proctor et al., High-dose ifosfamide in combination with etoposide and epirubicin (IVE) inthe treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy, EUR J HAEMA, 66, 2001, pp. 28-32

Authors: Robbie, L Berry, S Moir, E Booth, NA Culligan, D Tighe, J Watson, H King, D Bennett, B

Citation: L. Robbie et al., Myeloid leukaemic cells can lyse fibrin directly, BR J HAEM, 111(2), 2000, pp. 524-529

Authors: Shah, SAA Ormerod, AD Husain, A Kohle, P Culligan, D

Citation: Saa. Shah et al., Primary cutaneous CD30 (Ki-1)-positive anaplastic large cell lymphoma associated with renal cell carcinoma, BR J DERM, 140(5), 1999, pp. 971-972

Authors: Bowen, DT Denzlinger, C Brugger, W Culligan, D Gelly, K Adlakha, S Groves, M Hepburn, M Kanz, L

Citation: Dt. Bowen et al., Poor response rate to a continuous schedule of Amifostine therapy for 'low/intermediate risk' myelodysplastic patients, BR J HAEM, 103(3), 1998, pp. 785-787